Seres Therapeutics Inc (MCRB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.00 (-2.44%), Market cap $0.07B, 52-week low–high $6.77 ~ $28.63.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a liv
Financial statements, price targets, institutional (13F) holdings and related news for Seres Therapeutics Inc are updated in real time on BlackAll Trade.
Seres Therapeutics Inc trades at $4.00 (-2.44%). Real-time quotes and charts are available on BlackAll Trade.
Seres Therapeutics Inc has a market cap of about $0.07B.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize